CD44是参与细胞粘附和迁移的主要细胞表面受体。 CD44 的过度表达是许多肿瘤（包括脑膜瘤）的不良预后因素。本研究的目的是探讨CD44基因表达与原发性脑膜瘤临床特征之间的关联。通过快速冷冻从106例原发性脑膜瘤患者获得的肿瘤组织来定量评估CD44基因表达。分析了 CD44 表达与脑膜瘤临床特征（包括组织学恶性程度、肿瘤体积和瘤周脑水肿 (PTBE)）之间的关系。使用Steinhoff分类（SC）系统（从SC 0到SC III）评估PTBE。WHO 2级和3级脑膜瘤中CD44基因表达显着高于1级脑膜瘤。此外，CD44表达随着PTBE的严重程度而增加。特别是，在1级脑膜瘤或小尺寸肿瘤（最大肿瘤直径<43 mm）中，重度PTBE（SC II或III）肿瘤中CD44的表达显着高于无或轻度PTBE肿瘤（SC 0或III）。我）。多因素logistic回归分析还显示，CD44的过表达是原发性脑膜瘤中严重PTBE发展的独立显着因素。除了肿瘤细胞的侵袭性外，CD44表达还促进脑膜瘤中PTBE的发展。由于PTBE是脑膜瘤患者肿瘤相关癫痫或认知功能障碍的重要因素，因此CD44是PTBE脑膜瘤的潜在治疗靶点。

CD44 is a major cell surface receptor involved in cell adhesion and migration. The overexpression of CD44 is a poor prognostic factor in many neoplasms, including meningiomas. The aim of this study was to investigate the association between CD44 gene expression and clinical signatures of primary meningiomas.CD44 gene expression was quantitatively evaluated by snap freezing tumor tissues obtained from 106 patients with primary meningioma. The relationships between CD44 expression and clinical signatures of meningiomas, including histological malignancy, tumor volume, and peritumoral brain edema (PTBE), were analyzed. PTBE was assessed using the Steinhoff classification (SC) system (from SC 0 to SC III).CD44 gene expression in WHO grade 2 and 3 meningiomas was significantly higher than that in grade 1 meningiomas. In addition, CD44 expression increased with the severity of PTBE. Particularly, among the grade 1 meningiomas or small-sized tumors (maximum tumor diameter < 43 mm), CD44 expression in tumors with severe PTBE (SC II or III) was significantly higher than that in tumors without or with mild PTBE (SC 0 or I). Multivariate logistic regression analysis also revealed that overexpression of CD44 was an independent significant factor of severe PTBE development in primary meningiomas.In addition to tumor cell aggressiveness, CD44 expression promotes the development of PTBE in meningioma. Since PTBE is a strong factor of tumor-related epilepsy or cognitive dysfunction in patients with meningioma, CD44 is thus a potential therapeutic target in meningioma with PTBE.